|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2007-10-16
|
|
pubmed:abstractText |
We used decision analysis techniques with Markov cohort modeling to examine the role of cancer antigen 125 (CA-125) in follow-up surveillance strategies among patients with advanced ovarian cancer. Utilities were derived from a societal perspective.Using quality-adjusted life years (QALYS) as the outcome variable, the value of CA-125 monitoring for asymptomatic women with ovarian cancer was found to be reduced as compared with a strategy that includes CA-125 testing. Decisions to include CA-125 in surveillance strategies for ovarian cancer patients should be made after discussion with full disclosure of the preference-sensitive nature of CA-125. The model demonstrates that preferences and perspective can influence decisions in cancer care.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-10109801,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-10706647,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-11336573,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-12075699,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-1476141,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-15047231,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-15173101,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-2182963,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-2433652,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-2440307,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-2589442,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-2703180,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-3157319,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-3480655,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-6310399,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-7835797,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-8206398,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-8231333,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-8805927,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-8827972,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17938699-9633846
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:status |
PubMed-not-MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1198-0052
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
167-72
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model.
|
|
pubmed:affiliation |
Division of Gynecologic Oncology, University of Ottawa, Ottawa, Ontario. lahopkins@ottawahospital.on.ca
|
|
pubmed:publicationType |
Journal Article
|
